Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic defibrillator label warning on cellular phone use approved by FDA.

This article was originally published in The Gray Sheet

Executive Summary

MEDTRONIC DEFIBRILLATOR WARNING LABEL ON USE OF CELLULAR PHONES was approved by FDA on April 27. The premarket approval application supplement, which covers the company's PCD and Jewel implantable cardioverter defibrillators, establishes labeling that cautions against use of cellular phones in close proximity to the devices. Similar information already is contained in patient user manuals, Medtronic said.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT004133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel